Clinical Trials Logo
  1. Home
  2. Migraine Headaches
  3. NCT00442221

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

Migraine Headaches Clinical Trial

Official title:
An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

Clinical Trial Summary

The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines

Clinical Trial Description

The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines, with an optional second dose at least 2 hours following the first dose, if needed. Combo Formulation will be administered on average at least twice per month for 12 months. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00442221
Study type Interventional
Source POZEN
Contact
Status Completed
Phase Phase 3
Start date May 2004
Completion date August 2004
View Details
See also
  Status Clinical Trial Phase
Completed NCT06342232 - The Efficacy of Neurofeedback Mindfulness in Migraine Management N/A
Completed NCT02351544 - Prospective, Multi-Center Evaluation of the Efficacy of Peripheral Trigger Decompression Surgery for Migraine Headaches N/A
Completed NCT00665236 - Craniosacral Therapy in Migraine: A Feasibility Study N/A
Completed NCT01706003 - The Utility of Telemedicine in the Management of Migraine
Terminated NCT01944059 - Theramine® in the Prevention of Migraine Headache Phase 4
Terminated NCT01629329 - Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine Phase 4
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Not yet recruiting NCT05536635 - Effect of Breathing Techniques on Migraine Attacks and Severity N/A
Completed NCT02057315 - Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine Phase 1/Phase 2
Completed NCT00109083 - A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine Phase 2
Completed NCT02098499 - Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Phase 4
Completed NCT00714727 - Set Point Acupuncture for Migraines Using a Digital Assistant Phase 1
Completed NCT00434083 - To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches Phase 3
Completed NCT00960245 - Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions Phase 1
Completed NCT02856802 - An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) Phase 2
Completed NCT00355056 - PREMIUM Migraine Trial N/A
Completed NCT01118988 - Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents N/A
Completed NCT00433732 - To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches Phase 3
Completed NCT00750594 - Patent Foramen Ovale in Children With Migraine Headaches N/A